PharmedArtis

Together with our customers we strive to develop and produce improved biopharmaceuticals.

Considering the conditions of production as early as possible we reduce the time to commence clinical trials - and therefore time-to-market - and the associated costs. Our innovative capabilities make 2nd and 3rd generation biopharmaceuticals become available on a global scale.

Recombinant proteins have become an important part among Active Pharmaceutical Ingredients (APIs) for medicinal products (biopharmaceuticals).

For every medicinal product an effective and efficient production represents a central issue in terms of the production costs and its reduction. But for biotechnological APIs the production technology itself, i.e. upstream- and downstream-processing, can evolve as a real challenge.

The right choice of innovative expression hosts, improved vectors, sophisticated culture and novel purification strategies require state-of-the-art infrastructure, knowledge and experience to yield API of a constant and high quality.